FINWIRES · TerminalLIVE
FINWIRES

Pilgrim's Pride Likely Faces Margin Pressure in Q3, UBS Says

By

Pilgrim's Pride (PPC) is likely faced with margin pressure in Q3 amid a significant supply increase in the US chicken market this year, UBS said in a preview note Monday.

The report said pricing conditions weakened further in Q3, as the composite fell 4% quarter-on-quarter, while certain cuts posted sharper declines, including breast down 19% QoQ.

"Combined with higher feed costs, we expect this backdrop to have pressured PPC's 3Q US margins," the note said. "Looking ahead, the supply increase is set to continue."

UBS analysts said their EBIT and EBITDA estimates are below consensus due to the US business.

UBS kept its neutral rating and a $28 price target.

Price: $29.59, Change: $+0.11, Percent Change: +0.36%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA